As the likelihood of a flat budget increases for the 2024 fiscal year, NCI will have difficulty maintaining its current programs, the institute’s new director Kimryn Rathmell said in her inaugural NCI director’s report to members of the National Cancer Advisory Board Feb. 8.
The gridlock in Washington is taking a toll on federally funded cancer research as the partisan wrangling in Congress over border security and funding for Israel and Ukraine shows no sign of relenting.
Amid the gridlock that has seized Washington, NCI faces a grim and disturbing FY2024, the institute’s Principal Deputy Director Douglas R. Lowy said at the annual meeting of the Association of American Cancer Institutes.
The Office of the Secretary of Health and Human Services is coordinating a health informatics initiative—as part of the Cancer Moonshot—to set common data standards that could be used across key federal health agencies, including NCI, NIH, and FDA.
NCI continues to face the prospect of flat funding in fiscal year 2024 as a spending bill proposes a 3% cut to NCI’s budget, which threatens to further reduce the institute’s purchasing power, said NCI Director Monica Bertagnolli.
The probability of NCI receiving a boost in funds over the next two years is slim, NCI Director Monica Bertagnolli said at the joint meeting of the National Cancer Advisory Board and Board of Scientific Advisors June 14.
NCI has released the language of the much-discussed National Cancer Plan, an eight-goal blueprint that spans the spectrum of cancer care—prevention, treatment, and survivorship—to correspond with President Joe Biden’s vision of cutting cancer mortality by half in 25 years.
NCI is on the cusp of releasing designs for its National Cancer Plan, an initiative that would guide the institute’s mission and portfolio for years to come and engage everyone in oncology to “end cancer as we know it,” said NCI Director Monica Bertagnolli.
NCI is increasing the R01 payline to the 12th percentile in fiscal year 2023, up from the 11th percentile in FY22—bringing the institute’s payline to a level not seen since 2010.
It’s time to supercharge NCI’s role in redefining clinical trials and in strengthening the cancer research enterprise, NCI Director Monica Bertagnolli said Nov. 9 in her first director’s report.